Skip to main content
OpenTrials
Completed

NCT Number: NCT02725892

National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria

National, prospective, multicentric, non-interventional registry-based study, conducted among oncologists, pulmonologists in community and university hospitals, from the public sector in Algeria.

The study will collect information on the characteristics, and lung carcinomas patterns of patients whose lung cancer diagnosis was confirmed by a pathologist during the study period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Oncology & Epidemiology & Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Algiers, Algeria

Loading trial locations.

About this study

The study consists of:

  • All patients meeting inclusion/exclusion criteria presenting to their oncologists/pulmonologists for a routine visit during recruitment period will be sequentially asked to participate to the study.
  • The patients who do not consent will only be reported as new case of lung cancer for the incidence study.

The patients who consent to participate to the study will perform four in-hospital visits (Inclusion visit, visit at 3, 6 and 12 months). In addition to the 4 visits, a phone contact with the patients every 6 months at years 2,3, 4 and 5 will be done by the investigator or one of his/her authorised representative or the CRO or during a routine visit to the investigator, to check the patient's survival status.

THE STUDY DURATION 72 MONTHS

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
  • Aged at least18 years at diagnosis
  • Patients who provide their informed consent form

Exclusion criteria

  • Patients who did not provide the informed consent form
  • Patients with a mental or psychological disorder according to their treating clinicians

Treatment and study plan

NIS observational stud

Other

NIS observational study : Epidemiologic registry

Primary outcomes

  1. incidence of lung cancer

    Time frame: 12 months of recruitment period

    incidence of lung cancer, all types, stages and ages combined, in men and women newly diagnosed with lung cancer in Algeria over 12 months of recruitment period

Secondary outcomes

  1. incidence of newly diagnosed lung cancer

    Time frame: 12 month period

    • To characterise the incidence of newly diagnosed lung cancer in Algeria in a 12 month period according to patient and disease characteristics (Wilaya, sex, age, lung cancer type, stage disease and smoking status).

  2. survival

    Time frame: at 12, 24, 36, 48 and 60 months of follow-up.

  3. quality of life -EORTC QLQ-C30

    Time frame: baseline, 3, 6 and 12 months follow-up.

    To evaluate the quality of life of patients diagnosed with lung cancer in Algeria according to EORTC QLQ-C30 )

  4. Quality Of Life-EORTC QLQ- LC13

    Time frame: baseline, 3, 6 and 12 months follow-up.

    To evaluate the quality of life of patients diagnosed with lung cancer in Algeria according to EORTC QLQ- LC13

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

LuCaReAl: Lung Cancer Registry in Algeria.

Acronym: LuCaReAl

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
Apr 1, 2016
Registry last updated
Mar 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.